Table 2.

Total investigator-assessed response rates by disease characteristics following C1 + RC

	TGA (1,000 mg) n=15	TGB (2,000 mg) n=22	Total N=37
All patients, % (n/N)	47 (7/15)	68 (15/22)	59 (23/37)
Prior therapy, % (n/N)
Yes	42 (5/12)	69 (11/16)	57 (16/28)
No	67 (2/3)	67 (4/6)	67 (6/9)
Prior rituximab, % (n/N)
Yes	36 (4/11)	64 (9/14)	52 (13/25)
No	75 (3/4)	75 (6/8)	75 (9/12)
Baseline IgM level, % (n/N)
<4 g/dL	67 (6/9)	63 (10/16)	64 (16/25)
≥4 g/dL	17 (1/6)	83 (5/6)	50 (6/12)

IgM=immunoglobin M. TGA=Treatment Group A. TGB=Treatment Group B.